- Disease: Acute COVID-19
- Study type: Observational Cohort Study, Treatment
- Study type descriptors: Retrospective, Multicentre
- Objective: To assess the real-world use and outcomes of sotrovimab treatment in Belgium among patients with COVID-19 at high risk of developing severe disease
- Number of participants enrolled: 634
- Study enrolling from to
- Study includes follow-up for 29 days
- Standardisation: ICD-10, ATC
Sites (9)
- Center Hospitalier Universitaire Saint-Pierre (Brussels, Belgium)
- AZ Sint-Lucas (Ghent, Belgium)
- Erasmus Hospital (Brussels, Belgium)
- Jan Yperman Ziekenhuis (Ypres, Belgium)
- Ghent University Hospital (Ghent, Belgium)
- Damiaan Dicht bij het leven (Ostend, Belgium)
- AZ Maria Middelares (Ghent, Belgium)
- CHU Ambroise Paré (Mons, Belgium)
- AZ Groeninge (Kortrijk, Belgium)
Study Data
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Adolescents (12-17 years)
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Monoclonal antibodies
- Sotrovimab
External Links
Other information
Funders/Sponsors:
- GSK
- Vir Biotechnology
The information was provided with the aid of the study investigators
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to